Spectral Diagnostics (DIAGF) 0.2750 $DIAGF Cardiac

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2015 at 5:20 AM

Spectral Diagnostics (DIAGF) 0.2750 $DIAGF

Cardiac Marker Diagnostic Testing Markets 2015
M2 - Mon Feb 16, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3jhj5/cardiac_marker) has announced the addition of the "Cardiac Marker Diagnostic Testing Markets" report to their offering. Cardiac marker diagnostic testing measures the concentration of certain proteins, i.e., biomarkers, which indicate the presence or severity of cardiovascular disease (CVD). Among the most prevalent CVDs are sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis. Every year, an estimated 17 million people worldwide die from a CVD. This report describes the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker testing, including size; growth; industry trends; product development and investment; and clinical measurement devices, reagents and supplies. Highly-attractive cardiac marker areas of growth covered in this review include: the cardiac rapid assay market, troponins, Creatine kinase-myocardial band (CK-MB) and brain natriuretic peptide (BNP) testing. Also examined are heart failure, myoglobin, homocysteine (Hcy), C-reactive protein (CRP), pulmonary embolism (PE) (D-dimer test), low-density and high-density lipoproteins (LDL and HDL), stroke, cardiac enzymes, albumin, cardiac markers used in clinical decisions, cardiac markers in renal failure, cardiac panels and point of care (POC) cardiac markers. This study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing cardiac marker products in the U.S. and worldwide, as well as detailed tables, charts and figures covering the U.S., Europe and Asia markets. Key Topics Covered: 1. Overview 2. The Basics of Biomarkers 3. Cardiac Marker Testing Markets: Market Segment Analysis: Size, Growth and Share 4. Cardiovascular Disease Markers 5. Cardiac Marker Testing Development Issues 6. Business Trends in the Industry 7. Important Technology Trends 8. Company Profiles - Abbott Laboratories and SWOT Analysis - Alere and SWOT Analysis - Beckman Coulter (now part of Danaher) - Biosite, Inc. (now a brand of Alere) - bioM?rieux - CardioGenics - Chek Diagnostics - diaDexus and SWOT Analysis - Health-Chem Diagnostics (HCD) - LifeSign, LLC - Ortho-Clinical Diagnostics, Inc. and SWOT Analysis - PTS Diagnostics - PreMD, Inc. - Radiometer Medical - Randox Laboratories Ltd. - Response Biomedical - Roche Diagnostics - Sanyo Chemical Industries Ltd. - Shionogi & Co., Ltd. - Siemens Healthcare Diagnostics - Sierra Resources International - Spectral Diagnostics, Inc. For more information visit http://www.researchandmarkets.com/research/n3...iac_marker
ABT: 47.15 (+0.15), DHR: 84.98 (-0.48)

Spectral Announces Effective Date of Name Change
Marketwired - Tue Dec 16, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"

(TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that its previously announced name change to "Spectral Medical Inc." will be effective December 31, 2014. This new name will reflect the Company's continuing transition into a therapeutic development company, with a strategic focus on the development and commercialization of a treatment for severe sepsis and septic shock using our Endotoxin Activity Assay and the Toraymyxin(TM) ("PMX"

therapeutic.
SDI.TO: 0.34 (-0.01)

Spectral Announces Normal Course Issuer Bid
Marketwired - Mon Dec 15, 7:02AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"

(TSX: SDI)(OTCQX: DIAGF) a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that the Toronto Stock Exchange ("TSX"

has accepted Spectral's notice of intention to proceed with a normal course issuer bid through the facilities of the TSX.
SDI.TO: 0.34 (-0.01)

Largest Japanese Registry Data Analysis Demonstrates Significant Reduction in Mortality Rate of Septic Patients Treated With Toraymyxin(TM)
Marketwired - Tue Nov 25, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"

(TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced the presentation of the largest ever analysis of Japanese registry data on the significant mortality rate reduction in patients with septic shock treated with Toraymyxin(TM) ("PMX"

.The results of the study and analysis were presented at the American Society of Nephrology and support Spectral's EUPHRATES trial design.
SDI.TO: 0.34 (-0.01)

Spectral Diagnostics reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:15AM CST

Spectral Announces Third Quarter 2014 Results
Marketwired - Thu Nov 13, 7:07AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"

(TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced its unaudited financial results for the three and nine month periods ended September 30, 2014.
SDI.TO: 0.34 (-0.01)

Spectral Provides Update on Its Path to Commercialization
Marketwired - Wed Nov 05, 7:05AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"

(TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today provided an update on the Company's recent and upcoming activities, demonstrating a clear commercialization path to address the critical care needs of patients in a $3 billion market.
SDI.TO: 0.34 (-0.01)

Spectral to Exhibit at the Critical Care Canada Forum
CNW Group - Wed Oct 29, 7:00AM CDT
Dr. Claudio Ronco to discuss his analysis on the importance of endotoxin removal
SDI.TO: 0.34 (-0.01)

Spectral announces board changes
CNW Group - Wed Sep 24, 4:24PM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that Mr. William Stevens has been appointed to its Board of Directors.
SDI.TO: 0.34 (-0.01)

Spectral Announces Second Quarter, 2014 Results
CNW Group - Wed Aug 13, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepis and septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2014.
SDI.TO: 0.34 (-0.01)

Spectral Diagnostics and Toray Industries announce closing of Tranche "A" component of its up to $18.2 million Offering
CNW Group - Fri Jul 25, 8:26AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or"Spectral"

and Toray Industries, Inc. ("Toray"

today announced the closing of Tranche "A" of the previously announced non-brokered private placement of the Corporation (the "Offering"

. The Tranche "A" component of the Offering was comprised of 45,051,186 common shares of the Corporation ("Shares"

,at a subscription price of $0.293 per Share for aggregate proceeds of $13.2 million. The Offering was approved by shareholders of the Corporation at a special meeting of shareholders held on July 22, 2014.
SDI.TO: 0.34 (-0.01)

Spectral Diagnostics announces shareholder approval of its up to $18.2 million offering
CNW Group - Tue Jul 22, 1:26PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral"

today announced that at the special meeting (the "Special Meeting"

of shareholders ("Shareholders"

of the Corporation held earlier today, Shareholders overwhelmingly approved the terms of the previously announced proposed non-brokered private placement of the Corporation of up to $18.2 million (the "Offering"

.
SDI.TO: 0.34 (-0.01)

Spectral Announces ISS and Glass Lewis Recommendations to Vote in Favour of its up to $18.2 Million Offering
CNW Group - Tue Jul 08, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral"

today announced that both ISS Proxy Advisory Services and Glass Lewis & Co. have endorsed the previously announced non-brokered private placement of the Corporation of up to $18.2 million (the "Proposed Offering"

and recommend that shareholders of Spectral ("Shareholders"

vote "FOR" the Proposed Offering at the upcoming special meeting of Shareholders to be held on July 22, 2014.
SDI.TO: 0.34 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cure Blindness Project's 770K Screenings for World Sight Day

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

Purina Institute Highlights Nutritional Science at WSAVA 2026

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

TA Services Strengthens U.S.-Mexico Freight Operations

TA Services Moves Boldly Across Borders If ever there was a time to play the logistics chessboard like a champ, it's now, and TA Services just slammed the board with a solid move. They've grabbed Carmen Pacheco Transportation and Interload Forwarding, two family-run operations with some real muscle in North American logistics. This isn't a small-time maneuver; they've...

Bob Evans' Protein Mac & Cheese: Practical Power Play

Has anyone else noticed just how fast the world spins when it comes to consumer trends these days? Bob Evans is hopping right on the protein bandwagon with its latest launch, a microwave-ready Protein Macaroni & Cheese that packs 18 grams of protein per serving. You gotta hand it to them for seizing opportunity when they see it. This one's not just about tossing a new...

Community Banks Missing $106B Lending Opportunity?

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Navigating Holiday Sweets: Healthy Balancing Acts

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

Skandia's Soundproofing Kit Expands to Brazil's Skies

Soundproofing Takes Off in Brazil Skandia has just pulled off a neat trick, earning the nod from Brazil's National Civil Aviation Agency (ANAC) for their King Air soundproofing kit. That means quieter skies ahead for operators of the King Air 200 and 300 series in Brazil. This is no small feat, folks; it's like finally getting that coveted backstage pass after years of...

Epic Political Thriller Explores Humanity's Future

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

Pushing for National Liver Cancer Awareness in 2026

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...